Endpoint

Serum 25-hydroxyvitamin D concentration

CAT:outcome/serum-25-hydroxyvitamin-dreported in nmol/L15 findings from 1 compound

What moved it

15 findings · 1 compound · by evidence strength

Compound	Direction	Findings	Strongest evidence
calciol	up	15	Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.

Reported to move it

15 findings

calciol — increases
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×14
“Vitamin D3 supplementation increased post-randomization serum 25(OH)D concentrations as compared to the placebo (P-value for difference in trajectory: <0·0001).”
Quoted verbatim from Efficacy of vitamin D3 supplementation for the prevention of pulmonary tuberculosis and mortality in HIV: a randomised, double-blind, placebo-controlled trial..
Study

RCT
Duration

12 months
Dose

50,000 IU vitamin D3 weekly for four weeks, then 2000 IU daily to one year, versus matching placebo
Population

Adults living with HIV initiating antiretroviral therapy in Dar es Salaam, Tanzania, with baseline serum 25(OH)D below 30 ng/mL; random sample of 400 participants with serial 25(OH)D measures
Efficacy of vitamin D3 supplementation for the prevention of pulmonary tuberculosis and mortality in HIV: a randomised, double-blind, placebo-controlled trial.2020PMID:32621874Permalink
calciol — increases
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×14
“At Month 3 and 6, there was no significant difference between thrice-weekly vs. once-monthly cholecalciferol groups (P = 0.19 and 0.40, respectively), and both groups showed higher serum 25(OH)D levels than the placebo group (P < 0.001).”
Quoted verbatim from Effect of cholecalciferol on serum hepcidin and parameters of anaemia and CKD-MBD among haemodialysis patients: a randomized clinical trial..
Study

RCT
Duration

6 months
Dose

3,000 IU thrice weekly after dialysis, or once monthly 36,000 or 45,000 IU (equivalent to 9,000 IU/week)
Population

Haemodialysis patients on erythropoiesis-stimulating agents in Japan; both cholecalciferol regimens (3,000 IU thrice weekly and once-monthly, equivalent to 9,000 IU/week) compared with placebo at Months 3 and 6
Effect of cholecalciferol on serum hepcidin and parameters of anaemia and CKD-MBD among haemodialysis patients: a randomized clinical trial.2020PMID:32968158Industry fundedPermalink
calciol — increases
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×14
“25(OH)D was similar at baseline in the two groups, but higher in women randomized to cholecalciferol [68.2 nmol/l (standard deviation {SD} 21.9 nmol/l)] than placebo [43.4 nmol/l (SD 22.4 nmol/l)] at 34 weeks’ gestation (P < 0.001).”
Quoted verbatim from Does antenatal cholecalciferol supplementation affect the mode or timing of delivery? Post hoc analyses of the MAVIDOS randomized controlled trial..
Study

RCT
Dose

cholecalciferol 1000 IU/day orally, commenced before 17 weeks' gestation and continued until delivery
Population

Pregnant women over 18 years with a singleton pregnancy and screening 25(OH)D between 25 and 100 nmol/L, recruited at 11-14 weeks' gestation at three UK hospitals; 27.5% of the placebo group and 29.1% of the cholecalciferol group also used additional vitamin D supplements of up to 400 IU/day, and all received standard antenatal care.
Does antenatal cholecalciferol supplementation affect the mode or timing of delivery? Post hoc analyses of the MAVIDOS randomized controlled trial.2023PMID:36585903Industry fundedPermalink
calciol — increases
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×14
“Maternal postpartum vitamin D supplementation significantly increased infant serum 25(OH)D at 6 mo of age.”
Quoted verbatim from Basal Vitamin D Status and Supplement Dose Are Primary Contributors to Maternal 25-Hydroxyvitamin D Response to Prenatal and Postpartum Cholecalciferol Supplementation..
Study

RCT
Duration

6 months
Dose

maternal postpartum cholecalciferol 28,000 IU/week oral vs placebo, to 6 months postpartum
Population

infants at 6 months of age whose mothers received postpartum cholecalciferol supplementation
Basal Vitamin D Status and Supplement Dose Are Primary Contributors to Maternal 25-Hydroxyvitamin D Response to Prenatal and Postpartum Cholecalciferol Supplementation.2021PMID:34302350Permalink
calciol — increases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×14
“Mean serum 25(OH)D level increased from 27.9 ± 10.3 ng/mL at baseline to 54.9 ng/mL at 2 years in the vitamin D group and was unchanged (28.5 ± 10.0 ng/mL) in the placebo group.”
Quoted verbatim from Effects of Vitamin D Supplementation on Insulin Sensitivity and Secretion in Prediabetes..
Study

RCT
Duration

2 years
Dose

vitamin D3 4000 IU daily versus matching placebo for 24 months
Population

Overweight or obese adults with prediabetes at high risk for type 2 diabetes, mean age 60.5 years
Effects of Vitamin D Supplementation on Insulin Sensitivity and Secretion in Prediabetes.2022PMID:34473295Permalink
calciol — increases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×14
“Serum 25OH(D) levels increased in participants who received cholecalciferol supplementation compared with participants who received placebo (P = .006).”
Quoted verbatim from The Effects of Cholecalciferol Supplementation on FGF23 and α-Klotho in Hemodialysis Patients With Hypovitaminosis D: A Randomized, Double-Blind, Placebo-Controlled Trial..
Study

RCT
Duration

3 months
Dose

50,000 IU cholecalciferol weekly for 12 weeks
Population

Hemodialysis patients with hypovitaminosis D
The Effects of Cholecalciferol Supplementation on FGF23 and α-Klotho in Hemodialysis Patients With Hypovitaminosis D: A Randomized, Double-Blind, Placebo-Controlled Trial.2022PMID:34294550Permalink

Show the remaining 9

calciol — increases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×14
“After 12 weeks of cholecalciferol supplementation, mean (SD) 25(OH)D concentration increased from 15.0 (8.0) to 31.0 (7.1) ng/mL, but remained unchanged in the control group (14.0 (7.1) to 11.6 (7.5) mg/mL).”
Quoted verbatim from Cholecalciferol supplementation to improve the hepatitis B vaccination response in hemodialysis patients: A first randomized open label pilot study (DeVitaHep)..
Study

RCT
Duration

3 months
Dose

28,000 IU cholecalciferol orally weekly for 12 weeks
Population

Unvaccinated hemodialysis patients with 25(OH)D insufficiency (<30 ng/mL)
Cholecalciferol supplementation to improve the hepatitis B vaccination response in hemodialysis patients: A first randomized open label pilot study (DeVitaHep).2021PMID:34802788Permalink
calciol — increases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×14
“After a 12-week intervention, there was a significant increase in serum 25(OH)D levels in both groups, with the increase being higher in the cholecalciferol group than in the placebo group (49.05 vs. 24.01 ng/mL; P < 0.001).”
Quoted verbatim from Effect of cholecalciferol supplementation on hand grip strength, walking speed, and expression of vitamin D receptor, interleukin-6, and insulin-like growth factor-1 in monocyte in pre-frail older adults: A randomized double-blind placebo-controlled trial..
Study

RCT
Duration

3 months
Dose

cholecalciferol 4000 IU/day for 12 weeks
Population

pre-frail older adults; all participants also received calcium lactate 500 mg/day
Effect of cholecalciferol supplementation on hand grip strength, walking speed, and expression of vitamin D receptor, interleukin-6, and insulin-like growth factor-1 in monocyte in pre-frail older adults: A randomized double-blind placebo-controlled trial.2024PMID:38644647Permalink
calciol — increases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×14
“Cholecalciferol supplementation increased total 25OHD after 150 days compared to placebo and the difference was highest in men with lowest vitamin D status.”
Quoted verbatim from Influence of cholecalciferol supplementation on changes in total 25OHD, free 25OHD, and free 25OHD % in relation to calcium, bone, and glucose homeostasis in young, infertile men..
Study

RCT
Duration

5 months
Dose

oral bolus of 300,000 IU cholecalciferol followed by 1400 IU daily for 150 days
Population

young, infertile men
Influence of cholecalciferol supplementation on changes in total 25OHD, free 25OHD, and free 25OHD % in relation to calcium, bone, and glucose homeostasis in young, infertile men.2024PMID:39577708Permalink
calciol — increases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×14
“Serum 25(OH)D concentration increased significantly from baseline to 12 weeks (P < 0·05) in all the groups with no change at 24 weeks but further increase at 36 weeks (P < 0·05).”
Quoted verbatim from Efficacy and safety of various oral regimens (three oral doses) and schedules (daily v. monthly) of cholecalciferol in North Indian adults with low vitamin D status: evidence from a randomised controlled trial..
Study

RCT
Duration

8 months
Population

Healthy, vitamin D-deficient adults aged 18-60 years, pooled across four oral cholecalciferol dose/schedule arms (600 μg/d to 60 000 μg/month)
Efficacy and safety of various oral regimens (three oral doses) and schedules (daily v. monthly) of cholecalciferol in North Indian adults with low vitamin D status: evidence from a randomised controlled trial.2023PMID:35983775Permalink
calciol — increases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×14
“25OHD levels increased with cholecalciferol supplementation, with 85% achieving normal levels.”
Quoted verbatim from Changes in bone biomarkers in response to different dosing regimens of cholecalciferol supplementation in children with chronic kidney disease..
Study

RCT
Population

Children with CKD stages 2-4 and vitamin D deficiency, pooled across daily, weekly and monthly oral cholecalciferol dosing regimens
Changes in bone biomarkers in response to different dosing regimens of cholecalciferol supplementation in children with chronic kidney disease.2023PMID:36322258Permalink
calciol — increases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×14
“Provision of cholecalciferol-fortified skim milk increases serum total 25(OH)D concentrations in Colombian adolescents and adult women.”
Quoted verbatim from Increased Serum Total and Free 25-Hydroxyvitamin D with Daily Intake of Cholecalciferol-Fortified Skim Milk: A Randomized Controlled Trial in Colombian Adolescents..
Study

RCT
Duration

6 weeks
Dose

skim milk fortified with 2400 IU (60 microgram) cholecalciferol per litre, daily for 6 weeks
Population

Colombian adolescents and their mothers
Increased Serum Total and Free 25-Hydroxyvitamin D with Daily Intake of Cholecalciferol-Fortified Skim Milk: A Randomized Controlled Trial in Colombian Adolescents.2023PMID:37061343Permalink
calciol — increases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×14
“Cholecalciferol significantly increased serum levels of 25(OH)D and fetuin-A in the treatment group (p-value < 0.001), while no significant difference was observed in the placebo group.”
Quoted verbatim from The impact of cholecalciferol on markers of vascular calcification in hemodialysis patients: A randomized placebo controlled study..
Study

RCT
Dose

200,000 IU cholecalciferol per month, oral, for 3 months
Population

Hemodialysis patients
The impact of cholecalciferol on markers of vascular calcification in hemodialysis patients: A randomized placebo controlled study.2021PMID:33594986Permalink
calciol — increases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×14
“Dogs with PLE treated with cholecalciferol had higher 25OHD concentrations at T2 compared to dogs treated with placebo (225 nmol/L, range 72-434 vs. 80 nmol/L, range 31-254 nmol/L; p = 0.004).”
Quoted verbatim from Treatment of Hypovitaminosis D With Cholecalciferol in Dogs With Protein-Losing Enteropathies: A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial..
Study

animal · not in humans
Duration

4 weeks
Dose

400 IU/kg cholecalciferol PO daily for 6 weeks
Population

dogs with protein-losing enteropathy and decreased serum 25OHD, receiving standard PLE therapy in both arms
Treatment of Hypovitaminosis D With Cholecalciferol in Dogs With Protein-Losing Enteropathies: A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial.2025PMID:40485009Permalink
calciol — increases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×14
“Mean serum levels of 25-hydroxyvitamin D significantly increased after a single dose of vitamin D3 vs placebo (44.4 ng/mL vs 19.8 ng/mL; difference, 24.1 ng/mL [95% CI, 19.5-28.7]; P < .001).”
Quoted verbatim from Effect of a Single High Dose of Vitamin D3 on Hospital Length of Stay in Patients With Moderate to Severe COVID-19: A Randomized Clinical Trial..
Study

RCT
Dose

single oral dose of 200,000 IU vitamin D3 versus placebo
Population

Hospitalised adults with moderate to severe COVID-19 at two sites in Sao Paulo, Brazil
Effect 24.1 mean difference, 95% CI 19.5 to 28.7
Effect of a Single High Dose of Vitamin D3 on Hospital Length of Stay in Patients With Moderate to Severe COVID-19: A Randomized Clinical Trial.2021PMID:33595634Permalink

How it is measured

Serum or plasma 25-hydroxyvitamin D concentration by competitive immunoassay or by LC-MS/MS, as the achieved concentration on supplementation. The assay is recorded with each finding, since immunoassays and LC-MS/MS disagree systematically and handle the D2 form differently.

Measured, not recorded

Subject: serum 25-hydroxyvitamin d concentration
Measurements: 3 measurements
Recorded as a finding: No

Show what was measured

serum 25-hydroxyvitamin D concentration
increases, significant increase after supplementation
There was a significant increase in 25(OH)D levels after supplementation (p < 0.001); however, serum calcium (p = 0.02), phosphorus (p = 0.018), and iPTH (p = 0.03) were decreased.
PMID:35262225 · one of two readings recorded this
serum 25-hydroxyvitamin D concentration
increases, 17.93 to 24.41 ng/mL
Not recorded as a finding: within_arm_only — only the pre/post values inside the magnesium-treated group are reported; no control-group vitamin D values are given
In patients receiving magnesium supplementation, vitamin D levels significantly improved from 17.93 ± 8.96 to 24.41 ± 10.20 ng/mL (mean ± SD) (p < 0.05).
PMID:39380547 · one of two readings recorded this
serum 25-hydroxyvitamin D concentration
increases, 225 nmol/L vs 80 nmol/L at T2, p = 0.004
Dogs with PLE treated with cholecalciferol had higher 25OHD concentrations at T2 compared to dogs treated with placebo (225 nmol/L, range 72-434 vs. 80 nmol/L, range 31-254 nmol/L; p = 0.004).
PMID:40485009 · one of two readings recorded this

Sources cited

15 papers

Subject: serum 25-hydroxyvitamin d concentration
Findings: 15
Papers: 15